ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1349

Paternal Effects of Anti-TNFs in Inflammatory Arthritis

Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), Biologicals, pregnancy, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and spondyloarthritis (SpA) are included in this group. The use of anti-TNFs in arthritis has become very frequent, especially after the 2000s with established efficacy. However, their effects on fertility in men remain mostly unknown. In this study, we aimed to determine the effect of anti-TNFs on the fertility of men.

Methods: We performed a questionnaire on married male patients who were diagnosed between 1987-2020. The following questions were asked: Did your wife get pregnant while you were using an anti-TNF agent? How many times did she get pregnant? Which drug were you using when your wife got pregnant? Was there any problem during the pregnancy? Were you using any contraception? Have you ever been evaluated for infertility? What drug were you using during the time your wife could not get pregnant? Did you have any children when you were not taking anti-TNF treatments? After this questionnaire, we reevaluated the patient group who had pregnancy under anti-TNF treatment. We recorded any data regarding pregnancy complications and pregnancy-associated situations.

Results: 98 patients were involved in our study. The mean age of the patients was 54. 82 (80.39%) patients had AS, 12 (11.76%) patients had PsA, and 8 patients had RA. 72 patients did not experience pregnancy and 67 of them were using contraception (Figure 1). The number of patients taking anti-TNF treatments (infliximab, etanercept, golimumab, and adalimumab) who could not get pregnant despite trying to conceive was 5.Among those 5 patients, 4 were screened for infertility, revealing unknown etiology for 3, and the remaining 1 was of female origin. 2 of these 5 patients had already conceived and given birth before anti-TNF treatment. The patient who was not screened for infertility had been trying to conceive for the previous 2 months. The total number of conceptions was 50. There were 9 miscarriages under anti-TNF treatment and 5 curettages under anti-TNF treatment (four of them were voluntary and one of them was a medical requirement). There were 36 healthy births ( Figure 1). The patients who had miscarriages were using the following medications: certolizumab pegol (2 patients), golimumab (1 patient), etanercept (1 patient), adalimumab (1 patient), etanercept (3 patients), and infliximab (1 patient). The patient who had a curettage due to a medical requirement was using golimumab.

Conclusion: Among the male patients taking anti-TNF treatment, infertility due to paternal origin does not seem to be a major issue according to our limited data. Anti-TNF treatment thus seems to be safe with regards to fertility in male patients.

Supporting image 1

Figure 1.Flow chart of the patients according to conception


Disclosures: Z. Toker Dincer: None; B. Ates: None; A. Dag: None; I. Turkoglu: None; A. Ayla: None; S. Ugurlu: None.

To cite this abstract in AMA style:

Toker Dincer Z, Ates B, Dag A, Turkoglu I, Ayla A, Ugurlu S. Paternal Effects of Anti-TNFs in Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/paternal-effects-of-anti-tnfs-in-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/paternal-effects-of-anti-tnfs-in-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology